Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 450Stomach Neoplasms 295Rectal Neoplasms 271Colonic Neoplasms 192Pancreatic Neoplasms 177Neoplasm Metastasis 94Esophageal Neoplasms 88Carcinoma, Hepatocellular 60Adenocarcinoma Of Esophagus 47Cholangiocarcinoma 46Neoplasms 42Biliary Tract Neoplasms 38Gallbladder Neoplasms 31Adenocarcinoma 30Gastrointestinal Neoplasms 29Liver Neoplasms 25Esophageal Squamous Cell Carcinoma 23Carcinoma, Non-Small-Cell Lung 18Bile Duct Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 13Locally Advanced Rectal Cancer 13Colorectal Cancer Metastatic 11Appendiceal Neoplasms 11Recurrence 10Peritoneal Neoplasms 10Ovarian Neoplasms 9Carcinoma 7Breast Neoplasms 7Neurotoxicity Syndromes 6Gastrointestinal Diseases 6

Interventions

zirconium-89-trastuzumab 1STA 9090 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophagogastric Cancer × Oxaliplatin × Gastrointestinal × Clear all
NCT02296671 2016-03-08

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Washington University School of Medicine

Phase 2 Withdrawn
Gastrointestinal

Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡